FASTINOV technology was introduced into routine use at IPO Porto, bringing the company’s rapid antimicrobial susceptibility testing approach into the clinical infrastructure of an oncology hospital.
Why routine use matters
Routine implementation tests how a technology performs within the daily rhythm of a hospital laboratory. It requires clear sample pathways, trained users, defined review steps and communication between laboratory and clinical teams.
Supporting care for vulnerable patients
In oncology settings, timely microbiology information can be especially important because patients may be vulnerable to severe infection. Faster susceptibility information can support clinical teams as they refine treatment decisions, subject to the laboratory’s validated procedures and clinical judgement.
Introduction at IPO Porto marked an important step from evaluation toward routine hospital use of FASTINOV technology.